Background: Systemic sclerosis (SSc) is characterized in virtually all patients by anti-nuclear antibodies (ANA) with anti-centromere (ACA), anti-topoisomerase I (ant-Scl70), and anti-RNA polymerase III antibodies identifying patient subgroups. However, there are no reliable biomarkers predicting SSc susceptibility and internal organ involvement. Objectives: We aimed to identify serum protein biomarkers associated with SSc and interstitial lung disease (ILD), using a highly multiplexed proteomic technology.
Methods:
We analyzed serum samples of 3 patients with SSc and ILD (2 limited SSc: one ANA positive and one anti-Scl70 positive, and one diffuse SSc anti-Scl70 positive), 3 patients with SSc and no ILD (ACA positive limited SSc), and 4 healthy controls. All subjects were women and age matched. Serum proteomics profiling was performed using the SOMAscan platform (SomaLogic, Inc., Boulder, CO, USA). Statistical analysis included Student's t-test and were performed using the SomaSuite software (SomaLogic, Boulder, CO, USA). Results: Proteomic analysis identified 33 proteins which differentiate SSc from HC and 9 proteins which differentiate SSc patients with and without ILD. Compared to healthy controls, SSc cases showed an altered expression of proteins involved in extracellular matrix formation and cell-cell adhesion, angiogenesis, and lymphocyte recruitment, activation, and signaling, while an overall inhibition of neutrophil function was noted. An interferon and IL-1 signatures were also found. Patients with SSc and ILD manifested increased protein levels related to intracellular signaling and cell cycle, along with an increase of monocyte chemoattractants and ligands for the leukocyte adhesion compared to SSc without ILD. We further observed a decrease in B cell stimulating factor and IL-22 signaling in SSc with ILD. Background: In systemic sclerosis (SSc), systemic remodeling, microvascular injuries and production of autoantibodies are well known as disease hallmarks. However, the master regulator of these characteristics is still unclear. Microparticle (MP) is a small membrane vesicle, released from various kinds of cells, and distributes systemically through circulation 1) . Recent reports revealed that MP contains various growth factors, proteases and cytokines including TGF-b 2) , suggesting that MP can contribute to immune and mesenchymal responses as a conveyor 3) . and involve with disease process of SSc. Although, the possible involvement of MPs in the pathogenesis of SSc is indicated, the detailed association of MPs including MP subsets with SSc is not well clarified. Objectives: To elucidate the association between circulating MP subsets and patients' characteristic of SSc. Methods: Thirty-six patients with SSc and 13 healthy controls were involved in this study. Platelet-rich plasma containing microparticles was isolated from whole blood using gradient centrifugation and analyzed using flow cytometer. MP was defined as particles smaller than 1.0 μm diameter using Megamix ® , and identified each MP subsets based on expression of cell type-specific surface markers; platelet (CD31 + CD41 + ), endothelial cell (CD31 + CD41 -) and monocyte (CD14 + CD45 + ) using fluorescence-tagged antibodies. Clinical information was retrospectively collected from patients' records, and the correlation with the number of each MP subset was analyzed. Results: Mean age of 36 patients with SSc was 60.9±1.8 years, 94% was female, and mean disease duration was 11.2±9.5 years. Patients with diffuse cutaneous SSc (dcSSc) was 6 (17%). As for the proportion of MP subsets, platelet-derived MP (PMP) was the largest subset, followed by endothelial cell-derived MP (EMP) and monocyte-derived MP (MoMP) in all samples. In patients with SSc, the number of total MP and all MP subsets were higher than those in healthy controls (p<0.05). Also, all MP subsets were significantly higher in patients with dcSSc compared to limited cutaneous SSc (p<0.001). We also found that the number of PMP, EMP and MoMP were higher in patients who were positive against anti-topoisomerase I antibody than those negative (p<0.01, p<0.05 and p<0.05, respectively), whereas there were no significant differences in the numbers of each MP subset between the patients positive or negative against other SScspecific autoantibodies. In addition, the number of PMP and EMP were higher in patients with interstitial lung disease than those without (p<0.05). Moreover, all MP subsets were significantly inversely correlated with the percentage of predicted forced vital capacity (p<0.05, p<0.01, and p<0.01, respectively). Conclusions: These results suggest that MP subsets are associated with extended fibrotic phenotype in patients with SSc, and might be utilized as novel biomarkers. 
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